friday, may 18, 2018
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.in particular, the country has extreme levels of nitrogen dioxide due to heavily congested roads in urban areas,
.